China's clinical trial ecosystem is expanding rapidly as global sponsors seek faster development timelines and broader patient access. Contract research organizations (CROs) are key to this growth, yet compliance risks and complex regulatory demands persist under heightened oversight from Chinese authorities in 2025.

Recurring risks

Data integrity and quality management remain fundamental challenges. Manual data entry, often necessary due to limited access to hospital systems, creates vulnerabilities such as transcription errors and missing records. High turnover among clinical research coordinators and monitors disrupts continuity, leading to documentation gaps and incomplete handovers. Practices like retroactive signatures violate Good Clinical Practice standards, while protocol deviations, including visit window breaches and missed assessments, compromise trial reliability. These risks are amplified in institutions managing high trial volumes or operating with limited resources.

Regulatory tightening

The National Medical Products Administration's (NMPA) recent reforms underscore a shift toward comprehensive quality governance. The NMPA's 2025 update to the Inspection Points for Clinical Trials of Medical Devices expanded review criteria to 72 items covering trial conditions, subject protection, and data traceability. Severe non-compliance now triggers independent review, with consequences such as application rejection or certificate revocation. NMPA's inspection criteria are increasingly focused on institutions with high project volumes and areas most vulnerable to data integrity failures. At the same time, ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate) are being promoted as the gold standard for ensuring data quality throughout the clinical trial process.

Anti-bribery enforcement

Compliance pressures extend beyond operational risks. The State Administration for Market Regulation's 2025 Compliance Guidelines for Healthcare Companies to Prevent Commercial Bribery Risks and supporting cases issued by Shanghai AMR highlight bribery schemes in clinical research, including cash payments, share transfers to trial directors, and inflated "consulting fees" for fictitious projects. Violations under the Anti-Unfair Competition Law and Drug Administration Law can result in severe penalties, including personal liability, fines up to RMB 1 million, and lifetime bans for responsible personnel.

Practical considerations for sponsors

Sponsors should take a proactive, risk-based approach by thoroughly vetting CROs for quality systems, staffing capacity, and compliance history; conducting regular audits to monitor protocol adherence and data integrity; and reviewing financial arrangements to prevent bribery risks. Contracts should clearly define accountability and include contingency plans for nonconformities. As China's regulatory environment becomes more complex, sponsors that prioritize robust governance and collaborative risk management will be best positioned to ensure compliance, safeguard patient safety, and advance global drug development.